Corporate Announcements

Posted by Burton on July 7th, 2016 in Headlines Corporate Announcements  ⟩  0 comments

Lee Biosolutions is proud to announce the acquisition of the product lines of Creative Laboratory Products (CLP). a bulk manufacturer of lipoproteins and triglycerides for research and IVD manufacturing. The CLP team, with decades of lipoprotein manufacturing experience, will be joining the Lee Bio team at our St. Louis, MO-based manufacturing facility to build upon our extensive portfolio of proteins, enzymes and biochemicals for the life science and diagnostic manufacturing markets.
The lipid panel (cholesterol, triglycerides) is among the most widely-tested analyte grouping in the world today and is invaluable in detection and diagnosis of heart disease and other cardiovascular conditions. This aligns with Lee Bio’s goal to provide high quality reagents to the In vitro diagnostic market, to allow for better, more accurate testing around the globe. Applications of our lipoprotein product lines include, but are not limited to:
  • Manufacturing of liquid and lyophilized-stable controls, calibrators and standards
  • Additives for quality control serum and plasma
  • Cell culture media

Lee Biosolutions is a global biotechnology leader specializing in custom and bulk manufacturing and preparation of high quality finished enzymes, related proteins and biologicals used in clinical diagnostic tests for pathologies such as cardiac disease, cancer, diabetes, urine analysis, obesity, inflammation, neurological, autoimmune diseases, immunological disorders and more The company is known internationally for developing some of the most successful formulations for research, diagnostic and therapeutic markets. Lee Biosolutions is certified to ISO 13485:2003 and ISO 9001:2008 standards.


You can learn more about the company, its products, services and career opportunities by visiting its website at http://www.leebio.com

Below you’ll find a basic listing of our most popular “off the shelf” products, but we are able to customize our manufacturing to suit any demand you may have.
LipoproteinsSourcePart NumberTotal Cholesterol
Low Density Lipoprotein (LDL)
Concentrate, 0.45 μm filteredHuman Plasma360-10> 4,000 mg/dL
Concentrate, 0.22 μm filteredHuman Plasma360-12> 3,000 mg/dL
High Density Lipoprotein (HDL)
Concentrate, 0.45 μm filteredHuman Plasma361-10> 1,500 mg/dL
Concentrate, 0.22 μm filteredHuman Plasma361-123,000 - 4,000 mg/dL
Cholesterol Concentrate
Concentrate, 0.22 μm filtered, primarily HDL - "BCC"Bovine Serum185-103,000 - 7,000 mg/dL
Concentrate, 0.22 μm filtered, LDL/HDL blend - "BCCL"Bovine Serum185-20> 3,000 mg/dL
TriglyceridesSourcePart NumberTotal Triglyceride
Fraction, 0.45 μm filtered - "HTF"Human Plasma361-56> 12,000 mg/dL
Fraction - "ATF"Chicken Egg Yolk571-11> 15,000 mg/dL
Posted by Burton on March 25th, 2016 in Headlines Corporate Announcements  ⟩  0 comments

 

Lee Biosolutions is proud to announce the purchase of Creative Laboratory Products, Inc, complete product line. CLP was an Indianapolis, Indiana-based producer of human and animal cholesterol concentrates, such as Low Density Lipoprotein (LDL), High Density Lipoprotein(HDL) and delipidized serum products and sold the product line to Lee Biosolutions, Inc, on March 14th, 2016.

We are very happy to have their manufacturing team headed by Jason Proksch join Lee Biosolutions . Lee Bio will be assisting them with their move to St. Louis, MO. Transfer of technology and equipment to Lee Biosolutions manufacturing facility will be taking place during the next couple of months as the team wraps up current production. Lee Biosolutions will be utilizing CLP protocols and test methods, ensuring customers won’t be affected during the transition. Lee Bio team is preparing to perform Installation Qualifications (IQ) and Operational Qualifications (OQ) on equipment and instrumentation that is used in the production and testing of these products.

Burton Lee, CEO of Lee Bio says, “Dr. Gary Proksch , founder of Creative Laboratory Products was the first person to recognize the future of the lipoprotein market 30 years ago and his technology in providing stable, high quality lipoproteins has enabled diagnostic manufacturers worldwide to produce hundreds of millions of cholesterol tests over the years that have saved lives and created the market as we know today."

Matt Lee, President and COO says, " The addition of Bovine HDL , Bovine LDL Cholesterol Concentrate, Human LDL and HDL, delipidized serum and related products strengthens and expands our core product line providing both significant growth and capabilities allowing us expand in key diagnostics markets."

The transition of manufacturing CLP products to Lee Biosolutions will ensure that customers will be provided with high quality and consistent long-term supply with increased capacity for decades to come. CLP and Lee Biosolutions have had a close relationship for over 30 years and Lee Biosolutions’ expertise with process development and purification of proteins derived from both animal and human sources makes this a perfect fit that will provide for a seamless transition for customers.

Lee Biosolutions is a global biotechnology leader specializing in custom and bulk manufacturing and preparation of high quality finished enzymes, related proteins and biologicals used in clinical diagnostic tests for pathologies such as cardiac disease, cancer, diabetes, urine analysis, obesity, inflammation, neurological, autoimmune diseases, immunological disorders and more The company is known internationally for developing some of the most successful formulations for research, diagnostic and therapeutic markets. Lee Biosolutions is certified to ISO 13485:2003 and ISO 9001:2008 standards.

You can learn more about the company, its products, services and career opportunities by visiting its website at http://www.leebio.com

Posted by Burton on February 10th, 2016 in Headlines Corporate Announcements  ⟩  0 comments

Lee Biosolutions, a leader in the manufacture of finished enzymes and related proteins for the diagnostic and life science industry announces that it has achieved ISO 13485:2003 certification for the manufacture of biologics under clean room conditions for the medical industry. ISO 13485 is an international standard that certifies a company's quality management system for regulatory purposes and addresses the development, implementation and maintenance of a quality system that is intended for use by medical device manufacturers.

Lee Biosolutions achieved ISO 13485 following significant investment in a new expanded facility and putting together an incredible team that was committed to exceeding the requirements needed to meet compliance.  Our Regulatory Affairs Manager, Kevin Doss and Quality Assurance Manager, Jon Klein were instrumental in our success and continue to guide our team in making our organization a world class organization.

Burton Lee, CEO says " We have a responsibility to our clients and the industry to continue to invest in our processes and personnel for critical raw materials that  meet industry and regulatory requirements that reduce  risk, improves safety, while increasing quality and capabilities with continued improvements.   

Matt Lee, President and COO says " Our customers are increasingly calling on us to assist them in meeting the growing demands of the industry regulators in both US and in Europe.  We are now able to custom manufacture ISO 13485 certified critical raw materials which will benefit our customers who are developing new and innovative products for the medical industry.  ISO 13485 shows our ability to maintain an effective quality management system which benefits not only the client but the industry."

Lee Biosolutions is a producer of high purity finished enzymes and related proteins used by research institutions, IVD diagnostic manufacturers and the biotech healthcare industries worldwide. LeeBio is known for its expertise, leadership and support by clients because of its ability to closely partner with them in the development, purification, scale up and commercialization of innovative products. LeeBio has both ISO 13485:2003 and ISO 9001:2008 Certifications.

Posted by Burton on August 12th, 2015 in Corporate Announcements  ⟩  0 comments

Lee Biosolutions is a healthcare biotech company that manufactures finished proteins for the research and clinical diagnostic and life science market.Today we are proud to announce the promotion of Matthew Lee as President and Chief Operating Officer.  Burton Lee will maintain his role as CEO and focus on strategic planning.

Burton Lee, Chief Executive Officer of Lee Biosolutions stated, " Matt’s leadership skills and business acuity has helped us maintain double digit growth and increased profitability allowing us to expand our operations. His dedication to our team, vendors and customers has made this management move as the most logical choice in order to maximize our potential for growth.”  

Matthew Lee holds a B.S. in Marketing Management from Missouri State University and joined Lee Biosolutions in 2012 as Logistics Manager. He was promoted to Vice-President of Business Operations in 2014 for his ability to improve operational efficiencies in the business. He is currently on the Board of Directors and not only continue running the day to day operations but will assist the CEO in applying creative solutions to strategic challenges.

About Lee Biosolutions, Inc.

We are a global healthcare biotech company that specializes in process development and bulk manufacturing of finished human and animal enzymes and related proteins for research and clinical diagnostic tests. Our products are used for such pathologies as cardiac disease, cancer, diabetes, urine analysis, coagulation, obesity, inflammatory, neurological, autoimmune diseases and immunological disorders. Our expertise includes process optimization and scale-up, bioanalytical development, validation and purification of biologicals. We are known for our ability to take a bench top pilot process and scale up to commercialization that is efficient and cost effective for our clients.

Posted by Burton on August 3rd, 2015 in Uncategorized Headlines Corporate Announcements  ⟩  0 comments

To Whom It May Concern,

We are pleased to announce that we will officially move to a larger facility on August 10th.Please amend your records to our new contact details.

New Physical Address:

Lee Biosolutions, Inc.10850 Metro Ct, Maryland Heights, MO 63043

New Mailing Address:

Lee Biosolutions, IncPO Box 1569, Maryland Heights, MO 63043

Our new 41,000 sq. Ft facility will allow us to meet our growth projections by tripling our capacity, adding new employees and providing better service to our customers and vendors. We will not accept any deliveries to our old facility at 2924 Mary Ave after August 4th.If you have any questions please email info@leebio.com

Burton Lee

 CEO